Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (15)
  • Apoptosis
    (5)
  • GSK-3
    (2)
  • Aurora Kinase
    (1)
  • Autophagy
    (1)
  • JAK
    (1)
  • MEK
    (1)
  • PKC
    (1)
  • Trk receptor
    (1)
  • Others
    (3)
Filter
Search Result
Results for "

cdk7-cyclin h

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    19
    TargetMol | Inhibitors_Agonists
  • PROTAC Products
    2
    TargetMol | PROTAC
Samuraciclib hydrochloride
ICEC0942 hydrochloride, CT7001 hydrochloride
T108981805789-54-1
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold higher than CDK1, CDK2 (IC50 is 578 nM), CDK5 and CDK9 respectively. Samuraciclib hydrochloride inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. Samuraciclib hydrochloride has anti-tumor effects.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
pha-793887
PHA793887, PHA 793887
T2113718630-59-2
PHA-793887 has been used in trials studying the treatment of Advanced Metastatic Solid Tumors.
  • Inquiry Price
Size
QTY
sns-032
SNS032, BMS-387032
T6049345627-80-7
SNS-032 (BMS-387032) is a selective inhibitor of CDK2 (IC50: 48 nM), exhibiting 10- and 20-fold selectivity over CDK1 and CDK4, respectively. It is also sensitive to CDK7 (IC50: 62 nM) and CDK9 (IC50: 4 nM), with no effect on CDK6.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Milciclib
PHA-848125
T6081802539-81-7
Milciclib (PHA-848125) (PHA-848125) is a potent, ATP-competitive CDK inhibitor for CDK2 with IC50 of 45 nM. It is >3-fold more selective for CDK2 than CDK1, 2, 4, 5, and 7. Phase 2.
  • Inquiry Price
Size
QTY
Seliciclib
R-roscovitine, Roscovitine, CYC202
T2095186692-46-6
Seliciclib (Roscovitine) is a potent inhibitor of Cdk2 cyclin E (IC50=0.1 µM). Seliciclib also inhibits Cdk7 cyclin H, Cdk5 p35 and Cdc2 cyclin B (IC50=0.49 0.16 0.65 µM). Seliciclib has antitumor activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
lerociclib
G1T-38, G1T38, G1T 38
T113451628256-23-4
Lerociclib (G1T38) is a selective and highly potent CDK4 6 inhibitor with anticancer and antitumor activity, inhibits CDK4 CyclinD1 and CDK6 CyclinD3, and inhibits tumor growth in an animal model of endocrine-resistant breast cancer. Due to the poor solubility, for animal studies, the salt form T11345L is recommended.
  • Inquiry Price
8-10 weeks
Size
QTY
Lerociclib dihydrochloride
G1T38 dihydrochloride
T11345L2097938-59-3
Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective CDK4 CDK6 inhibitor, with IC50 values of 2 nM for CDK6 CyclinD3 and 1 nM for CDK4 CyclinD1.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
(R)-CR8 trihydrochloride
CR8, (R)-Isomer trihydrochloride
T126171786438-30-9
(R)-CR8 trihydrochloride (CR8, (R)-Isomer trihydrochloride) is a CDK1 2 5 7 9 inhibitor that acts as a molecular glue degrader with neuroprotective activity and induces apoptosis.
  • Inquiry Price
7-10 days
Size
QTY
(R)​-​CR8
CR8, (R)-Isomer
T12617L294646-77-8
(R)-CR8 ((R)-Isomer) is a potent and selective CDK inhibitor.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
CDK12-IN-E9
T149152020052-55-3
CDK12-IN-E9 is a cell cycle protein kinase (CDK) inhibitor with anticancer and antitumor activity that can be used in the study of breast cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
CGP60474
T14943164658-13-3
CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently.
  • Inquiry Price
4-6 weeks
Size
QTY
NU6140
T16359444723-13-1
NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity.
  • Inquiry Price
Size
QTY
Roniciclib
BAY 1000394
T167841223498-69-8
Roniciclib (BAY 1000394) is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol L.
  • Inquiry Price
Size
QTY
ykl-5-124
T224611957203-01-8
YKL-5-124, a potent, selective and covalent CDK7 inhibitor with an IC50 of 9.7 nM, 1300 nM and 3020 nM for CDK7 Mat1 CycH, CDK2 and CDK9 respectively, displays biochemical and cellular selectivity for CDK7 over CDK12 13.
  • Inquiry Price
Size
QTY
RGB-286638 free base
T2378784210-88-4
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM 2 nM 3 nM 4 nM 5 nM for cyclin T1-CDK9 cyclin B1-CDK1 cyclin E-CDK2 cyclin D1-CDK4 cyclin E-CDK3 p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
  • Inquiry Price
Size
QTY
cdk6/pim1-in-1
T630712677026-14-9
CDK6 PIM1-IN-1 is a balanced, potent dual inhibitor of CDK6 (IC50: 39 nM) and PIM1 (IC50: 88 nM), also showing inhibitory activity on CDK4 (IC50: 3.6 nM). It significantly inhibits the proliferation of acute myeloid leukemia (AML) cells, arrests the cell cycle in G1 phase, induces cell apoptosis, and demonstrates anti-AML activity.
  • Inquiry Price
6-8 weeks
Size
QTY
ulecaciclib
T633622075750-05-7
Ulecaciclib is an orally active, blood-brain barrier-transparent, cell cycle protein-dependent kinase (CDK) inhibitor that exhibits favorable pharmacokinetic profiles, with ki of 0.62 μM (CDK2 Cyclin A), 3 nM (CDK6 Cyclin D3), 0.2 nM (CDK4 Cyclin D1) and 0.63 μM (CDK7 Cyclin H) for CDKs. D1) and 0.63 μM (CDK7 Cyclin H).
  • Inquiry Price
6-8 weeks
Size
QTY
Ibulocydine
T709881314096-68-8
Ibulocydine is a potent CDK inhibitor. Ibulocydine has high activity against Cdk7 cyclin H Mat1 and Cdk9 cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7 9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively ind......
  • Inquiry Price
6-8 weeks
Size
QTY
JSH-0009 dimaleate
T881702559759-04-3
  • Inquiry Price
10-14 weeks
Size
QTY